Masimo, now part of Danaher, has received FDA 510(k) clearance for Root with LiDCO and the Masimo LiDCO Sensor, creating an integrated hemodynamic monitoring system that continuously trends oxygen delivery by combining cardiac output with noninvasive hemoglobin and arterial oxygen-saturation measurements. Oxygen delivery, generally expressed as DO₂, represents the amount of oxygen transported to tissues over time rather than merely the pressure or volume of blood moving through the circulation. Masimo says the new configuration brings together LiDCO cardiac-output monitoring, SpHb noninvasive hemoglobin and Masimo SET pulse oximetry to generate continuous, beat-to-beat information on how changes in circulation and oxygen-carrying capacity affect tissue oxygen supply.
The clearance addresses an important limitation in conventional perioperative monitoring. Blood pressure can look acceptable even when cardiac output is inadequate, while cardiac output alone does not reveal how much oxygen each liter of blood actually carries. Hemoglobin concentration and oxygen saturation determine that content, but hemoglobin has traditionally been measured intermittently through laboratory blood samples. By combining continuously updated values, Masimo is attempting to show clinicians changes in the entire oxygen-transport equation rather than requiring them to infer tissue oxygenation from several measurements collected at different times.
Why does normal blood pressure not guarantee that tissues are receiving enough oxygen?
Blood pressure is essential for perfusion, but pressure and flow are not synonymous. A patient can maintain an apparently acceptable arterial pressure through vasoconstriction while cardiac output falls, particularly during surgery, bleeding, dehydration or cardiovascular instability.
Even adequate cardiac output does not guarantee adequate oxygen delivery if hemoglobin concentration is low or oxygen saturation falls. The physiological relationship is multiplicative: oxygen delivery depends on how much blood the heart pumps and how much oxygen that blood can carry.
This means clinicians can face situations where one monitored variable remains reassuring while the combined oxygen-delivery state is deteriorating. Masimo’s DO₂ calculation attempts to make that integrated physiology continuously visible.
The concept is particularly relevant during major surgery, where fluid shifts, blood loss, anesthesia and changing vascular tone can affect several components simultaneously.
Why has continuous DO₂ been difficult to monitor?
Cardiac output can be measured through invasive or minimally invasive hemodynamic systems, and pulse oximetry provides continuous arterial oxygen-saturation estimates. Hemoglobin has historically been the missing continuously available component because concentration is commonly obtained through intermittent laboratory blood samples.
That creates temporal gaps. A patient’s cardiac output can change within minutes while the most recent hemoglobin result reflects a sample obtained much earlier.
Masimo’s SpHb technology estimates hemoglobin continuously using noninvasive optical measurements. Integrating that value with LiDCO cardiac output and SpO₂ allows Root to update the estimated oxygen-delivery picture continuously rather than waiting for the next laboratory draw.
Noninvasive hemoglobin should still be understood within its clinical limitations. A continuous trend can be useful for recognizing change, but clinicians may still rely on laboratory measurement when precise hemoglobin values determine transfusion or other major treatment decisions.
What is LiDCO actually measuring?
LiDCO is a hemodynamic monitoring technology used to derive cardiac output and related measures from the arterial blood-pressure waveform. Cardiac output represents the amount of blood the heart pumps per minute, and changes can signal whether a patient is responding to fluid administration, vasoactive medicines or other interventions.
The advantage of continuous hemodynamics is not simply displaying another number. It gives clinicians a dynamic view of whether treatment is increasing effective circulation and whether the cardiovascular system is becoming more or less stable.
Adding DO₂ creates a higher-level variable from those measurements. A fluid bolus might increase cardiac output, but if hemoglobin is very low, oxygen delivery may remain inadequate. Conversely, transfusing blood can increase oxygen-carrying capacity even if cardiac output changes little.
This is the clinical reasoning Masimo is attempting to put onto one monitoring platform rather than leaving entirely to manual interpretation.
What does the concept of “oxygen debt” mean in high-risk surgery?
Tissues require continuous oxygen for cellular metabolism. When oxygen delivery falls below demand, anaerobic metabolism increases and a deficit can accumulate over time. Critical-care literature has described this cumulative deficit as oxygen debt and linked prolonged or severe oxygen debt with organ dysfunction and poor outcomes.
Masimo cites older randomized studies in high-risk surgery showing improved outcomes when clinicians deliberately optimized oxygen delivery. One 138-patient trial reported mortality of 3% in a preoperative optimization group compared with 17% in controls, while another 107-patient study reported a large relative mortality reduction with protocolized increases in DO₂.
Those studies establish the physiological importance of oxygen delivery but were conducted decades before the newly cleared Masimo configuration and do not constitute randomized evidence that the current Root/LiDCO system itself reduces mortality.
That distinction is important. FDA has cleared the monitoring function; it has not established that continuous DO₂ display produces the same clinical-outcome benefit as historic goal-directed therapy protocols.
Could continuous oxygen delivery change transfusion decisions?
Potentially, but it should not be interpreted as an automated transfusion trigger. Hemoglobin remains one of the principal parameters clinicians consider when deciding whether a bleeding or anemic patient may need red blood cells, yet transfusion decisions also depend on symptoms, hemodynamics, ongoing blood loss and clinical context.
A patient with relatively low hemoglobin but strong cardiac output and oxygen saturation may have adequate DO₂, while another patient with a higher hemoglobin level but failing cardiac output could still have poor tissue oxygen delivery.
Continuous integration could therefore provide useful context around the laboratory number. It might help clinicians understand whether a falling hemoglobin trend is beginning to compromise overall oxygen transport or whether interventions are restoring delivery.
Prospective studies will be needed to determine whether using the combined DO₂ display actually reduces unnecessary transfusions, improves fluid management or changes complications.
Why is this commercially relevant to Danaher after acquiring Masimo?
Masimo brings Danaher into advanced bedside and operating-room monitoring, complementing a portfolio historically strong in diagnostics and life-science tools. Root already functions as a modular patient-monitoring platform, allowing new measurements and algorithms to be added without requiring a completely separate bedside monitor for every physiological variable.
That architecture means each FDA-cleared capability can increase the clinical utility of an installed platform. LiDCO adds hemodynamics, SpHb contributes continuous hemoglobin and SET provides oxygen saturation, while software can integrate those streams into a derived metric clinicians could otherwise calculate only intermittently.
The competitive advantage depends on whether hospitals value that integration enough to change purchasing or workflow. Major anesthesia and critical-care systems already provide extensive hemodynamic information, and clinicians may prefer validated individual variables to composite measures unless the integrated DO₂ trend demonstrates clear decision value.
What evidence would make continuous DO₂ monitoring clinically transformative?
The strongest studies would randomize high-risk surgical or critical-care patients to usual monitoring versus a protocol using continuous DO₂ and test whether the additional information changes meaningful outcomes. Potential endpoints could include acute kidney injury, complications, transfusion, ICU stay, organ failure or mortality.
Researchers would also need to establish actionable thresholds. A continuous number becomes far more useful when clinicians know which decline requires intervention and which reflects harmless physiological variability.
That is the next evidentiary layer Masimo now has the regulatory ability to pursue. The FDA clearance makes continuous DO₂ available as a clinical monitoring function, but utility will depend on whether teams respond to the information in ways that improve care.
The conceptual advance is nonetheless important. For decades, operating rooms have monitored blood pressure, saturation and intermittent hemoglobin as separate pieces of physiology. Masimo’s newly cleared configuration asks clinicians to watch the final transport objective more directly: not merely whether there is pressure, blood flow or oxygen in the blood, but how much oxygen those variables are delivering to the patient’s tissues together.
